There is no cure for genital herpes, but Genocea is getting closer to marketing an immunotherapy that could control herpes symptoms. The Massachusetts-based company announced Wednesday that it met its goals in a Phase II study of its investigational GEN-003 vaccine.
Genocea Biosciences' GEN-003 vaccine is well-positioned to compete in the genital herpes treatment market. It's in a better position, in fact, than Agenus' HerpV, according to a GlobalData analyst.
After hitting its primary endpoint in a Phase II study last fall, Agenus was already leading a Sanofi-NIH collaboration in efforts to develop the first genital herpes vaccine. Now, it's built on that lead with new Phase II results for its therapeutic candidate, HerpV, which achieved statistical significance in reducing viral load.
Agenus and a Sanofi-NIH collaboration both gave updates on their genital herpes vaccine candidates this week. The Agenus vaccine, HerpV, is leading the race, having met its primary endpoint in a Phase II trial of 80 subjects, 70 of whom received the treatment.
A trial of 8,323 women revealed that a vaccine designed to prevent genital herpes was only able to partially protect women from one strain of the virus, according to research published in The New
Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The